XBiotech Inc. — Key Metrics
5 years of history · ending 2023-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)↓-105.6% -$15
$-1
Book Value Per Share↓-55.9% -$9
$7
Free Cash Flow Per Share↓-57.2% -$0
$-1
Cash Per Share↓-57.4% -$9
$7
Revenue Per Share
$0
OCF Per Share↓-56.0% -$0
$-1
Return on Equity↓-178.5pts
-10.7%
Return on Assets↓-165.7pts
-10.4%
Return on Invested Capital↓-5.6pts
-12.9%
Current Ratio↑+177.9% +$21
33.07
Quick Ratio↑+177.9% +$21
33.07
Asset Turnover
0.00
Days Sales Outstanding
110.68
Days Payables Outstanding
1350.11
R&D / Revenue
786.6%
SBC / Revenue
126.2%
Capex / Revenue
14.6%
Working Capital↓-70.2% -$460M
$196M
Net Current Asset Value↓-70.4% -$461M
$194M
Invested Capital↓-71.0% -$537M
$219M
OCF / Net Income↑+2890.6% +$1
0.76
FCF / Net Income↑+2913.1% +$1
0.78
Accruals Ratio (Sloan)↓-86.7pts
-2.6%
Net Debt↑+72.0% +$515M
$-200M
Net Debt / EBITDA↓-77.4% -$19
5.59
Interest Coverage
—
Cash Coverage
—
Dividend Coverage
0.93
Capex Coverage↑+42.2% +$38
-51.73
Tangible Common Equity↓-71.0% -$537M
$219M
TCE / Total Assets↑+4.1pts
96.6%
NOPAT↓-1.9% -$566K
$-30M
Cash ROIC↓-3.7pts
-8.3%
WC / Revenue
5381.0%
Capex / D&A↑+146.4% +$0
0.21
Reinvestment Rate↓-3.3pts
3.6%
Total Payout Ratio↓-0.1pts
-0.1%
Asset Growth vs Revenue Growth
92.1%
Book Value 5Y CAGR↓-27.0pts
39.5%
Stock Price (FY-end)↓-75.1% -$12
$4
Market Cap↓-83.7% -$623M
$122M
P/E Ratio
1.11
P/S Ratio
26.64
P/B Ratio↓-43.6% -$0
0.56
P/TB Ratio↓-43.6% -$0
0.56
P/OCF Ratio
4.82
P/FCF Ratio
5.07
Enterprise Value↓-357.9% -$109M
$-78M
EV / Sales
-27.59
EV / FCF
1.48
FCF Yield↓-13.2pts
-15.7%
Dividend Yield
0.0%
Shareholder Yield↓-2.2pts
-2.7%
Buyback Yield
0.0%
R&D Yield↑+23.7pts
27.0%
Capex Yield↑+0.3pts
0.3%
Dividend Per Share
$0
Graham Number
$73
Shares Variation (YoY)↓-29.4pts
-0.0%
Beta (5Y)↑+20.1% +$0
0.90
Cost of Equity↑+0.8pts
9.0%
52W High↓-62.9% -$11
$6
52W Low↓-29.7% -$1
$3
Trailing Return 1Y↓-240.0pts
27.4%
Trailing Return 5Y
-6.4%
F-Score (Piotroski)↑+0.0% +$0
3.00
Z-Score (Altman)↑+7.8% +$1
9.57
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.